Protection of the elderly from pneumococcal pneumonia with a protein-based vaccine?

Mechanisms of Ageing and Development

Volumn 125, Issue 2, 2004, Pages 129-131

  Briles, David E ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Pneumococcal pneumonia; Protein based vaccine; Vaccine

Indexed keywords

ANTIBODY; CROSS REACTING ANTIGEN; MEMBRANE PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCAL SURFACE PROTEIN C; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYSACCHARIDE; PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

AGED; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM; CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FATALITY; GERIATRIC PATIENT; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LOBAR PNEUMONIA; MOLECULE; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VIRULENCE;

EID: 0842281256     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2003.11.008     Document Type: Conference Paper

References (21)

1. Balachandran P., Brooks-Walter A., Virolainen-Julkunen A., Hollingshead S.K., Briles D.E. The role of pneumococcal surface protein C (PspC) in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70:2002;2526-2534.
2. Benton K., Everson M., Briles D. A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect. Immun. 63:1995;448-455.
3. Benton K., VanCott J., Briles D.E. Role of tumor necrosis factor alpha in the host response of mice to bacteremia caused by pneumolysin-deficient pneumococci. Infect. Immun. 66:1998;839-842.
4. Berry A.M., Paton J.C. Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect. Immun. 64:1996;5255-5262.
5. Briles, D.E., Paton, J.C., Nahm, M.H., Swiatlo, E., 2000a. Immunity to Streptococcus pneumoniae. In: Cunningham, M., Fujinami, R.S. (Eds.), Effect of Microbes on the Immune System. Lippincott-Raven, Philadelphia, pp. 263-280.
6. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., Virolainen A., Swiatlo E., Hollingshead S.K. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68:2000b;796-800.
7. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., Ferguson L.M., Nahm M.H., Nabors G.S. Immunization of humans with rPspA elicits antibodies, which passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182:2000c;1694-1701.
8. Briles D.E., Nabors G.S., BrooksWalter A., Paton J.C., Hollingshead S. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine. 19:2001;S87-S95.
9. Cornu C., Yzebe D., Leophonte P., Gaillat J., Boissel J.P., Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine. 19:2001;4780-4790.
10. Dintilhac A., Alloing G., Granadel C., Claverys J.-P. Competence and virulence of S. pneuminiae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of metal permeases. Mol. Microbiol. 25:1997;727-739.
11. Hollingshead S.K., Becker R.S., Briles D.E. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect. Immun. 68:2000;5889-5900.
12. Lomholt H. Evidence for recombination and an antigenically diverse immunoglobulin A1 protease among strains of Streptococcus pneumoniae. Infect. Immun. 63:1995;4238-4243.
13. McDaniel L.S., Scott G., Kearney J.F., Briles D.E. Monoclonal antibodies against protease sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J. Exp. Med. 160:1984;386-397.
14. Mitchell T.J., Andrew P.W., Saunders F.K., Smith A.N., Boulnois G.J. Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein. Mol. Microbiol. 5:1991;1883-1888.
15. Ogunniyi A.D., Folland R.L., Briles D.B., Hollingshead S.K., Paton J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect. Immun. 68:2000;3028-3033.
16. Paton J.C. The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Trends Microbiol. 4:1996;103-106.
17. Paton J.C., Rowan-Kelly B., Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysin. Infect. Immun. 43:1984;1085-1087.
18. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., Adair R.K., Clemmens J.D. Protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1991;1453-1460.
19. Shinefield H., Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr. Infect. Dis. J. 19:2000;394-397.
20. Tu A.-H., Fulgham R., McCory M., Briles D.E., Szalai A.J. Pneumococcal surface protein A (PspA) inhibits complement activation by Streptococcus pneumoniae. Infect. Immun. 67:1999;4720-4724.
21. Watson L., Wilson B.J., Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine. 20:2002;2166-2173.